Search

Your search keyword '"El-Messaoudi S"' showing total 212 results
Start Over Author "El-Messaoudi S"
212 results on '"El-Messaoudi S"'

3. Dual-Pathway Inhibition with Rivaroxaban and Low-Dose Aspirin Does Not Alter Immune Cell Responsiveness and Distribution in Patients with Coronary Artery Disease

Author

Groh, L.A., Willems, L.H., Fintelman, P., Reijnen, M., El Messaoudi, S., Warle, M.C., Groh, L.A., Willems, L.H., Fintelman, P., Reijnen, M., El Messaoudi, S., and Warle, M.C.

Abstract

Contains fulltext : 305509.pdf (Publisher’s version ) (Open Access), INTRODUCTION: Cardiovascular diseases (CVD) are the leading cause of death globally. Inflammation is an important driver of CVD where tissue damage may lead to the formation of deadly thrombi. Therefore, antithrombotic drugs, such as platelet inhibitors, are crucial for secondary risk prevention in coronary artery disease (CAD) and peripheral artery disease (PAD). For severe forms of the disease, dual-pathway inhibition (DPI) where low-dose aspirin is combined with rivaroxaban has shown improved efficacy in reducing cardiovascular mortality. METHODS: Given this greater improvement in mortality, and the importance of inflammation in driving atherosclerosis, the potential for off-target inflammation-lowering effects of these drugs was evaluated by looking at the change in immune cell distribution and responsiveness to ex vivo lipopolysaccharide (LPS) stimulation after 3 months of DPI in patients with CAD. RESULTS: We observed no changes in whole blood or peripheral blood mononuclear cell (PBMC) immune cell responsiveness to LPS after 3 months of DPI. Additionally, we did not observe any changes in the distribution of total white blood cells, monocytes, neutrophils, lymphocytes, or platelets during the study course. Signs of systemic inflammation were studied using Olink proteomics in 33 patients with PAD after 3 months of DPI. No changes were observed in any of the inflammatory proteins measured after the treatment period, suggesting that the state of chronic inflammation was not altered in these subjects. CONCLUSION: Three months of DPI does not result in any meaningful change in immune cell responsiveness and distribution in patients with CAD or PAD. TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT05210725.

Published
2024

4. Two-Week Interruption of Statin Therapy Results in an Exaggerated Inflammatory Monocyte Phenotype in Young Patients With Myocardial Infarction Without Standard Modifiable Risk Factors

Author

Mol, Jan-Quinten, Tuijl, Julia van, Bekkering, S., Rodwell, L., Pop, Gheorghe A. M., Netea, M.G., Royen, N. van, Riksen, N.P., El Messaoudi, S., Mol, Jan-Quinten, Tuijl, Julia van, Bekkering, S., Rodwell, L., Pop, Gheorghe A. M., Netea, M.G., Royen, N. van, Riksen, N.P., and El Messaoudi, S.

Abstract

Contains fulltext : 307416.pdf (Publisher’s version ) (Open Access)

Published
2024

5. Evaluation of left cardiac chamber function with cardiac magnetic resonance and association with outcome in patients with systemic sclerosis.

Author

Butcher, S.C., Vos, J.L., Fortuni, F., Galloo, X., Liem, S.I.E., Bax, J.J., Delgado, V., Vonk, M.C., Leuven, S.I. van, Snoeren, M.M., El Messaoudi, S., Vries-Bouwstra, J.K. de, Nijveldt, R., Ajmone Marsan, N., Butcher, S.C., Vos, J.L., Fortuni, F., Galloo, X., Liem, S.I.E., Bax, J.J., Delgado, V., Vonk, M.C., Leuven, S.I. van, Snoeren, M.M., El Messaoudi, S., Vries-Bouwstra, J.K. de, Nijveldt, R., and Ajmone Marsan, N.

Abstract

Item does not contain fulltext, OBJECTIVE: This study aimed to determine whether lower values of feature-tracking cardiovascular magnetic resonance (CMR)-derived left atrial reservoir strain (LARS) and impaired left ventricular (LV) global longitudinal strain (GLS) were associated with the presence of symptoms and long-term prognosis in patients with SSc. METHODS: A total of 100 patients {54 [interquartile range (IQR) 46-64] years, 42% male} with SSc who underwent CMR imaging at two tertiary referral centres were included. All patients underwent analysis of LARS and LV GLS using feature-tracking on CMR and were followed-up for the occurrence of all-cause mortality. RESULTS: The median LV GLS was -21.8% and the median LARS was 36%. On multivariable logistic regression, LARS [odds ratio (OR) 0.964 per %, 95% CI 0.929, 0.998, P = 0.049] was independently associated with New York Heart Association (NYHA) class II-IV heart failure symptoms. Over a median follow-up of 37 (21-62) months, a total of 24 (24%) patients died. Univariable Cox regression analysis demonstrated that LARS [hazard ratio (HR) 0.94 per 1%, 95% CI 0.91, 0.97, P < 0.0001) and LV GLS (HR 1.10 per %, 95% CI 1.03, 1.17, P = 0.005) were associated with all-cause mortality, while LV ejection fraction was not. Likelihood ratio tests demonstrated that LARS provided incremental value over prognostically important clinical and imaging parameters, including late gadolinium enhancement. CONCLUSION: In patients with SSc, LARS was independently associated with the presence of NYHA class II-IV heart failure symptoms. Although both LARS and LV GLS were associated with all-cause mortality, only LARS provided incremental value over all evaluated variables known to be prognostically important in patients with SSc.

Published
2023

7. Future steps in cardio-oncology-a national multidisciplinary survey among healthcare professionals in the Netherlands.

Author

Koop, Y., Teske, A.J., Wanders, I., Meijer, H.J.M., Kaanders, J.H.A.M., Manintveld, O.C., Hassing, H.C., Vermeulen, H., Maas, A.H.E.M., Spronsen, D.J. van, Atsma, F., El Messaoudi, S., Koop, Y., Teske, A.J., Wanders, I., Meijer, H.J.M., Kaanders, J.H.A.M., Manintveld, O.C., Hassing, H.C., Vermeulen, H., Maas, A.H.E.M., Spronsen, D.J. van, Atsma, F., and El Messaoudi, S.

Abstract

01 augustus 2023, Item does not contain fulltext, BACKGROUND: The awareness of cancer therapy-related adverse cardiac effects is fueled by recent literature on cardiotoxicity incidence and detection strategies. Although this influences the sense of urgency, in current practice, cardiotoxicity monitoring and treatment is not structurally performed. With this study, we aimed to evaluate current perspectives on cardio-oncology and to assess needs, ultimately to determine an agenda for improvements in current practice. MATERIAL AND METHODS: A national multidisciplinary 36-question survey was conducted. The survey was developed by a multidisciplinary team, theoretically based on an implementation checklist and distributed by email, through cardiology and oncology societies as well as social media. RESULTS: One hundred ninety professionals completed the survey, of which 66 were cardiologists, 66 radiation oncologists, and 58 medical oncologists and hematologists. Many professionals were unaware of their specialisms' cardio-oncology guidelines: 62.1% of cardiologists and 29.3% of the hematologists and medical oncologists respectively. Many cardiologists (N = 46; 69.7%), radiation oncologists (N = 45; 68.2%), and hematologists and medical oncologists (N = 38; 65.5%) expressed that they did not have sufficient knowledge to treat cardio-oncology patients and would either refer a patient or aspire to gain more knowledge on the topic. CONCLUSION: The field of cardio-oncology is advancing rapidly, with progress in stratification and detection strategies leading to the development of new guidelines and consensus statements. However, the application of these guidelines in current practice appears to be lagging. Professionals express a need for additional training and a practical guideline including risk stratification, monitoring, and treatment strategies. Multidisciplinary discussion and consensus on cardio-oncology care is vital to improve implementation of cardio-oncology guidelines, ultimately to improve cardiac care for onco

Published
2023

8. Diastolic delta best predicts paravalvular regurgitation after transcatheter aortic valve replacement as assessed by cardiac magnetic resonance: the APPOSE trial.

Author

Rooijakkers, M.J.P., Stens, N.A., Wely, M.H. van, Wulp, K. van der, Rodwell, L., Gehlmann, H.R., Garsse, L.A. van, Geuzebroek, G.S.C., Verkroost, M.W.A., Habets, J., El Messaoudi, S., Thijssen, D.H.J., Nijveldt, R., Royen, N. van, Rooijakkers, M.J.P., Stens, N.A., Wely, M.H. van, Wulp, K. van der, Rodwell, L., Gehlmann, H.R., Garsse, L.A. van, Geuzebroek, G.S.C., Verkroost, M.W.A., Habets, J., El Messaoudi, S., Thijssen, D.H.J., Nijveldt, R., and Royen, N. van

Abstract

Contains fulltext : 295984.pdf (Publisher’s version ) (Open Access), AIMS: Paravalvular regurgitation (PVR) is a common complication after transcatheter aortic valve replacement (TAVR) that poses an increased risk of rehospitalization for heart failure and mortality. The aim of this study was to assess the accuracy of haemodynamic indices to predict relevant PVR. METHODS AND RESULTS: In this prospective single-centre clinical trial, four haemodynamic indices of PVR measured during TAVR were assessed for their correlation with gold standard cardiac magnetic resonance (CMR)-derived regurgitant fraction (CMR-RF) at 1 month follow-up: diastolic delta (DD), heart rate-adjusted diastolic delta (HR-DD), aortic regurgitation index (ARI), and aortic regurgitation index ratio (ARI ratio). These haemodynamic indices were analysed for their ability to predict relevant PVR (defined as CMR-RF > 20%) using receiver operating characteristic (ROC) curves with corresponding area under the ROC curves (AUCs). A total of 77 patients were included and had CMR performed 41 ± 14 days after TAVR. Mean CMR-RF was 12.4 ± 9.3%. Fifteen (19.5%) patients had CMR-RF > 20%. DD had the best correlation with CMR-RF and the highest AUC to predict relevant PVR (0.82; 95% CI, 0.72-0.92), followed by HR-DD (AUC 0.78; 95% CI, 0.67-0.89), ARI (AUC 0.78; 95% CI, 0.66-0.89), and ARI ratio (AUC 0.65; 95% CI, 0.49-0.81). The optimal cut-off value for DD was 32 mmHg, with sensitivity of 69% and specificity of 77% in predicting relevant PVR. CONCLUSION: DD measured during TAVR best predicts relevant PVR. Correction for heart rate (HR-DD) or systolic blood pressure (ARI, ARI ratio) did not improve this predictive value.

Published
2023

9. Assessing the Novel Myval Balloon-Expandable Valve with the Evolut Valve: A Propensity-Matched Study.

Author

Halim, J., Rooijakkers, M.J.P., Heijer, P. den, Haddad, M. El, Branden, B. van den, Vos, J., Schölzel, B., Meuwissen, M., Gameren, M. van, El Messaoudi, S., Royen, N. van, Ijsselmuiden, S., Halim, J., Rooijakkers, M.J.P., Heijer, P. den, Haddad, M. El, Branden, B. van den, Vos, J., Schölzel, B., Meuwissen, M., Gameren, M. van, El Messaoudi, S., Royen, N. van, and Ijsselmuiden, S.

Abstract

Contains fulltext : 294750.pdf (Publisher’s version ) (Open Access), BACKGROUND: The Myval balloon-expandable (BE) valve has shown encouraging early clinical data in terms of safety and efficacy. Comparative data with other well-established contemporary valves are nonetheless still scarce. This study aims to compare the performance of the Myval BE valve with the Evolut self-expanding (SE) valve. METHODS: In this retrospective single-center study, 223 patients with symptomatic severe aortic stenosis (AS) were included and treated with the Myval BE valve (n = 120) or with the Evolut SE valve (n = 103). Then, 91 pairs were compared after matching. Clinical outcomes were evaluated at 30 days and 1 year. Echocardiographic follow-up was performed at 30 days. RESULTS: Procedural complications were rare in both groups. At the 30-day follow-up, no significant difference in cardiac death (Myval: 1% vs. Evolut: 2%, p = 0.56), stroke (2% vs. 4%, p = 0.41) and myocardial infarction (1% vs. 3%, p = 0.31) was observed. A permanent pacemaker implantation (PPI) was significantly less needed in the Myval group (4% vs. 15%, p = 0.01). At 1 year, cardiac death (2% vs. 4%, p = 0.41) and the stroke rate (7% vs. 5%, p = 0.76) were similar. Moderate-severe paravalvular leakage (PVL) was also comparable in both groups (1% vs. 4%, p = 0.17). CONCLUSION: Safety and efficacy outcomes were comparable between the two valves, except for a higher PPI rate for the Evolut SE valve. Up to 1-year follow-up, clinical outcomes showed acceptable rates of stroke and cardiac death with both valves. Valve hemodynamics were excellent with a low rate of moderate-severe PVL in both groups.

Published
2023

10. Peripheral blood mononuclear cell hyperresponsiveness in patients with premature myocardial infarction without traditional risk factors.

Author

Mol, J.H.Q., Tuijl, J. van, Bekkering, S., Heijden, C.D.C.C. van der, Damen, S.A.J., Cossins, B.C., Emst, J.E. van, Nielen, T.M., Rodwell, L., Li, Y., Pop, G.A.M., Netea, M.G., Royen, N. van, Riksen, N.P., El Messaoudi, S., Mol, J.H.Q., Tuijl, J. van, Bekkering, S., Heijden, C.D.C.C. van der, Damen, S.A.J., Cossins, B.C., Emst, J.E. van, Nielen, T.M., Rodwell, L., Li, Y., Pop, G.A.M., Netea, M.G., Royen, N. van, Riksen, N.P., and El Messaoudi, S.

Abstract

Contains fulltext : 294983.pdf (Publisher’s version ) (Open Access), An increasing number of patients develop an atherothrombotic myocardial infarction (MI) in the absence of standard modifiable risk factors (SMuRFs). Monocytes and macrophages regulate the development of atherosclerosis, and monocytes can adopt a long-term hyperinflammatory phenotype by epigenetic reprogramming, which can contribute to atherogenesis (called "trained immunity"). We assessed circulating monocyte phenotype and function and specific histone marks associated with trained immunity in SMuRFless patients with MI and matched healthy controls. Even in the absence of systemic inflammation, monocytes from SMuRFless patients with MI had an increased overall cytokine production capacity, with the strongest difference for LPS-induced interleukin-10 production, which was associated with an enrichment of the permissive histone marker H3K4me3 at the promoter region. Considering the lack of intervenable risk factors in these patients, trained immunity could be a promising target for future therapy.

Published
2023

11. Effect of ticagrelor and prasugrel on remote myocardial inflammation in patients with acute myocardial infarction with ST-elevation: a CMR T1 and T2 mapping study

Author

Konijnenberg, L.S.F., Zugwitz, D., Everaars, H., Hoeven, N.W.V., Demirkiran, A., Rodwell, L., Leeuwen, M.A.H. van, Rossum, A.C. van, El Messaoudi, S., Riksen, N.P., Royen, N. van, Nijveldt, R., Konijnenberg, L.S.F., Zugwitz, D., Everaars, H., Hoeven, N.W.V., Demirkiran, A., Rodwell, L., Leeuwen, M.A.H. van, Rossum, A.C. van, El Messaoudi, S., Riksen, N.P., Royen, N. van, and Nijveldt, R.

Abstract

Item does not contain fulltext, PURPOSE: Acute myocardial ischaemia triggers a non-specific inflammatory response of remote myocardium through the increase of plasma concentrations of acute-phase proteins, which causes myocardial oedema. As ticagrelor has been shown to significantly decrease circulating levels of several pro-inflammatory cytokines in patients after acute myocardial infarction with ST-elevation (STEMI), we sought to investigate a potential suppressive effect of ticagrelor over prasugrel on cardiac magnetic resonance (CMR) T1 and T2 values in remote myocardium. METHODS: Ninety STEMI patients were prospectively included and randomised to receive either ticagrelor or prasugrel maintenance treatment after successful primary percutaneous coronary intervention. Patients underwent CMR after 2-7 days. The protocol included long and short axis cine imaging, T1 mapping, T2 mapping and late gadolinium enhancement imaging. RESULTS: After excluding 30 patients due to either missing images or insufficient quality of the T1 or T2 maps, 60 patients were included in our analysis. Of those, 29 patients were randomised to the ticagrelor group and 31 patients to the prasugrel group. In the remote myocardium, T1 values did not differ between groups (931.3 [919.4-950.4] ms for ticagrelor vs. 932.6 [915.5-949.2] ms for prasugrel (p = 0.94)), nor did the T2 values (53.8 ± 4.6 ms for ticagrelor vs. 53.7 ± 4.7 ms for prasugrel (p = 0.86)). Also, in the infarcted myocardium, T1 and T2 values did not differ between groups. CONCLUSION: In revascularised STEMI patients, ticagrelor maintenance therapy did not show superiority over prasugrel in preventing early remote myocardial inflammation as assessed by CMR T1 and T2 mapping.

Published
2023

13. Colchicine and the Heart. Attenuating crystal-induced inflammation in atherosclerosis

Author

Cornel, J.H., Royen, N. van, El Messaoudi, S., Tijssen, J.G.P., Opstal, T.S.J., Cornel, J.H., Royen, N. van, El Messaoudi, S., Tijssen, J.G.P., and Opstal, T.S.J.

Abstract

Radboud University, 20 november 2023, Promotores : Cornel, J.H., Royen, N. van Co-promotores : El Messaoudi, S., Tijssen, J.G.P., Item does not contain fulltext

Published
2023

14. Colchicine and diabetes in patients with chronic coronary artery disease: insights from the LoDoCo2 randomized controlled trial.

Author

Mohammadnia, N., Los, J., Opstal, T.S.J., Fiolet, A.T.L., Eikelboom, J.W., Mosterd, A., Nidorf, S.M., Budgeon, C.A., Tijssen, J.G., Thompson, P.L., Tack, C.J.J., Simsek, S., Bax, W.A., Cornel, J.H., El Messaoudi, S., Mohammadnia, N., Los, J., Opstal, T.S.J., Fiolet, A.T.L., Eikelboom, J.W., Mosterd, A., Nidorf, S.M., Budgeon, C.A., Tijssen, J.G., Thompson, P.L., Tack, C.J.J., Simsek, S., Bax, W.A., Cornel, J.H., and El Messaoudi, S.

Abstract

Contains fulltext : 300044.pdf (Publisher’s version ) (Open Access), INTRODUCTION: Despite optimal treatment, patients with chronic coronary artery disease (CAD) and diabetes mellitus (DM) are at high risk of cardiovascular events, emphasizing the need for new treatment options. The Low-Dose Colchicine 2 (LoDoCo2) trial demonstrated that colchicine reduces cardiovascular risk in patients with chronic CAD. This analysis determines the efficacy of colchicine in patients with chronic CAD and DM as well as the effect of colchicine on the development of new-onset type 2 diabetes mellitus (T2DM). METHODS: The LoDoCo2 trial randomized 5,522 patients to placebo or colchicine 0.5 mg once daily, with a median follow-up of 28.6 months. The primary composite endpoint was cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven revascularization. The effect of its treatment in patients with and without DM was evaluated by including an interaction term in the model. RESULTS: A total of 1,007 participants (18.2%) had T2DM at baseline. The adjusted hazard ratio (HR) [(95% confidence interval (CI)] for the primary endpoint in the T2DM group was 1.52 (1.15-2.01, p < 0.01) compared with the group without T2DM. The HR for the treatment effect on the primary endpoint was 0.87 (0.61-1.25) in participants with T2DM and 0.64 (0.51-0.80) in participants without diabetes (p(interaction )= 0.14). The incidence of new-onset T2DM was 1.5% (34 out of 2,270) in the colchicine group and 2.2% (49 out of 2,245) in the placebo group (p = 0.10). DISCUSSION: In conclusion, based on the current evidence, the beneficial effects of colchicine on cardiovascular endpoints are consistent regardless of DM status. The potential benefits of colchicine in preventing new-onset DM need further investigation. These findings are only hypothesis-generating and require larger prospective trials to confirm the results.

Published
2023

16. Assessment of paravalvular regurgitation after transcatheter aortic valve replacement by hemodynamic measurements and cardiac magnetic resonance (APPOSE trial)

Author

Rooijakkers, M J P, primary, Stens, N A, additional, Van Wely, M H, additional, Van Der Wulp, K, additional, Rodwell, L, additional, Gehlmann, H, additional, Van Garsse, L A F M, additional, Geuzebroek, G S C, additional, Verkroost, M W A, additional, Habets, J, additional, El Messaoudi, S, additional, Thijssen, D H J, additional, Nijveldt, R, additional, and Van Royen, N, additional

Published
2022
Full Text
View/download PDF

18. The effects of colchicine in patients with diabetes mellitus and chronic coronary artery disease: a post-hoc analysis of the LoDoCo2-trial

Author

Mohammadnia, N, primary, Los, J, additional, Opstal, T S J, additional, Fiolet, A T L, additional, Eikelboom, J W, additional, Mosterd, A, additional, Nidorf, S M, additional, Budgeon, C A, additional, Tijssen, J G P, additional, Thompson, P L, additional, Tack, C J, additional, Simsek, S, additional, Bax, W A, additional, Cornel, J H, additional, and El Messaoudi, S, additional

Published
2022
Full Text
View/download PDF

19. End-of-trial inflammatory biomarkers, lipid levels, creatine kinase and markers of renal and liver function in the LoDoCo2 trial

Author

Van Broekhoven, A, primary, Mohammadnia, N, additional, Silvis, M J M, additional, Los, J, additional, Fiolet, A T L, additional, Opstal, T S J, additional, Mosterd, A, additional, Eikelboom, J W, additional, Nidorf, S M, additional, Bax, W A, additional, Tijssen, J G P, additional, De Kleijn, D P V, additional, Thompson, P L, additional, El Messaoudi, S, additional, and Cornel, J H, additional

Published
2022
Full Text
View/download PDF

20. Two week interruption of statin therapy results in an exaggerated inflammatory phenotype in young myocardial infarction patients without standard modifiable risk factors

Author

Mol, J H Q, primary, Van Tuijl, J, additional, Bekkering, S, additional, Stolk-Van Der Heijden, C, additional, Damen, S, additional, Cossins, B, additional, Van Emst, L, additional, Pop, G, additional, Netea, M, additional, Van Royen, N, additional, Riksen, N, additional, and El Messaoudi, S, additional

Published
2022
Full Text
View/download PDF

24. The Prognostic Value of Right Atrial and Right Ventricular Functional Parameters in Systemic Sclerosis

Author

Vos, J.L., Butcher, S.C., Fortuni, F., Galloo, X., Rodwell, L., Vonk, M.C., Bax, J.J., Leuven, S.I. van, Vries-Bouwstra, J.K. de, Snoeren, M.M., El Messaoudi, S., Marsan, N.A., Nijveldt, R., Vos, J.L., Butcher, S.C., Fortuni, F., Galloo, X., Rodwell, L., Vonk, M.C., Bax, J.J., Leuven, S.I. van, Vries-Bouwstra, J.K. de, Snoeren, M.M., El Messaoudi, S., Marsan, N.A., and Nijveldt, R.

Abstract

Item does not contain fulltext, INTRODUCTION: Right ventricular (RV) function is of particular importance in systemic sclerosis (SSc), since common SSc complications, such as interstitial lung disease and pulmonary hypertension may affect RV afterload. Cardiovascular magnetic resonance (CMR) is the gold standard for measuring RV function. CMR-derived RV and right atrial (RA) strain is a promising tool to detect subtle changes in RV function, and might have incremental value, however, prognostic data is lacking. Therefore, the aim of this study was to evaluate the prognostic value of RA and RV strain in SSc. METHODS: In this retrospective study, performed at two Dutch hospitals, consecutive SSc patients who underwent CMR were included. RV longitudinal strain (LS) and RA strain were measured. Unadjusted cox proportional hazard regression analysis and likelihood ratio tests were used to evaluate the association and incremental value of strain parameters with all-cause mortality. RESULTS: A total of 100 patients (median age 54 [46-64] years, 42% male) were included. Twenty-four patients (24%) died during a follow-up of 3.1 [1.8-5.2] years. RA reservoir [Hazard Ratio (HR) = 0.95, 95% CI 0.91-0.99, p = 0.009] and conduit strain (HR = 0.93, 95% CI 0.88-0.98, p = 0.008) were univariable predictors of all-cause mortality, while RV LS and RA booster strain were not. RA conduit strain proved to be of incremental value to sex, atrial fibrillation, NYHA class, RA maximum volume indexed, and late gadolinium enhancement (p < 0.05 for all). CONCLUSION: RA reservoir and conduit strain are predictors of all-cause mortality in SSc patients, whereas RV LS is not. In addition, RA conduit strain showed incremental prognostic value to all evaluated clinical and imaging parameters. Therefore, RA conduit strain may be a useful prognostic marker in SSc patients.

Published
2022

25. Long-Term Efficacy of Colchicine in Patients With Chronic Coronary Disease: Insights From LoDoCo2

Author

Opstal, T.S.J., Broekhoven, A. van, Fiolet, A.T.L., Mosterd, A., Eikelboom, J.W., Nidorf, S.M., Thompson, P.L., Budgeon, C.A., Bartels, L., Nooijer, R. de, Bax, W.A., Tijssen, J.G., El Messaoudi, S., Cornel, J.H., Opstal, T.S.J., Broekhoven, A. van, Fiolet, A.T.L., Mosterd, A., Eikelboom, J.W., Nidorf, S.M., Thompson, P.L., Budgeon, C.A., Bartels, L., Nooijer, R. de, Bax, W.A., Tijssen, J.G., El Messaoudi, S., and Cornel, J.H.

Abstract

Item does not contain fulltext

Published
2022

26. Mitral Annular Disjunction Assessed Using CMR Imaging: Insights From the UK Biobank Population Study

Author

Zugwitz, D., Fung, K., Aung, N., Rauseo, E., McCracken, C., Cooper, J., El Messaoudi, S., Anderson, R.H., Piechnik, S.K., Neubauer, S., Petersen, S.E., Nijveldt, R., Zugwitz, D., Fung, K., Aung, N., Rauseo, E., McCracken, C., Cooper, J., El Messaoudi, S., Anderson, R.H., Piechnik, S.K., Neubauer, S., Petersen, S.E., and Nijveldt, R.

Abstract

Item does not contain fulltext, BACKGROUND: Mitral annular disjunction is the atrial displacement of the mural mitral valve leaflet hinge point within the atrioventricular junction. Said to be associated with malignant ventricular arrhythmias and sudden death, its prevalence in the general population is not known. OBJECTIVES: The purpose of this study was to assess the frequency of occurrence and extent of mitral annular disjunction in a large population cohort. METHODS: The authors assessed the cardiac magnetic resonance (CMR) images in 2,646 Caucasian subjects enrolled in the UK Biobank imaging study, measuring the length of disjunction at 4 points around the mitral annulus, assessing for presence of prolapse or billowing of the leaflets, and for curling motion of the inferolateral left ventricular wall. RESULTS: From 2,607 included participants, the authors found disjunction in 1,990 (76%) cases, most commonly at the anterior and inferior ventricular wall. The authors found inferolateral disjunction, reported as clinically important, in 134 (5%) cases. Prolapse was more frequent in subjects with disjunction (odds ratio [OR]: 2.5; P = 0.02), with positive associations found between systolic curling and disjunction at any site (OR: 3.6; P < 0.01), and systolic curling and prolapse (OR: 71.9; P < 0.01). CONCLUSIONS: This large-scale study shows that disjunction is a common finding when using CMR. Disjunction at the inferolateral ventricular wall, however, was rare. The authors found associations between disjunction and both prolapse and billowing of the mural mitral valve leaflet. These findings support the notion that only extensive inferolateral disjunction, when found, warrants consideration of further investigation, but disjunction elsewhere in the annulus should be considered a normal finding.

Published
2022

28. Innate immune cells in the pathophysiology of calcific aortic valve disease: lessons to be learned from atherosclerotic cardiovascular disease?

Author

Broeders, W., Bekkering, S., El Messaoudi, S., Joosten, L.A.B., Royen, N. van, Riksen, N.P., Broeders, W., Bekkering, S., El Messaoudi, S., Joosten, L.A.B., Royen, N. van, and Riksen, N.P.

Abstract

Contains fulltext : 251910.pdf (Publisher’s version ) (Open Access), Calcific aortic valve disease (CAVD) is the most common valvular disease in the developed world with currently no effective pharmacological treatment available. CAVD results from a complex, multifactorial process, in which valvular inflammation and fibro-calcific remodelling lead to valve thickening and cardiac outflow obstruction. The exact underlying pathophysiology of CAVD is still not fully understood, yet the development of CAVD shows many similarities with the pathophysiology of atherosclerotic cardiovascular disease (ASCVD), such as coronary artery disease. Innate immune cells play a crucial role in ASCVD and might also play a pivotal role in the development of CAVD. This review summarizes the current knowledge on the role of innate immune cells, both in the circulation and in the aortic valve, in the development of CAVD and the similarities and differences with ASCVD. Trained immunity and clonal haematopoiesis of indeterminate potential are proposed as novel immunological mechanisms that possibly contribute to the pathophysiology of CAVD and new possible treatment targets are discussed.

Published
2022

29. Breast Cancer: Mind the Heart

Author

Maas, A.H.E.M., Vermeulen, H., Atsma, F., El Messaoudi, S., Koop, Y., Maas, A.H.E.M., Vermeulen, H., Atsma, F., El Messaoudi, S., and Koop, Y.

Abstract

Radboud University, 14 oktober 2022, Promotores : Maas, A.H.E.M., Vermeulen, H. Co-promotores : Atsma, F., El Messaoudi, S., Contains fulltext : 281491.pdf (Publisher’s version ) (Open Access)

Published
2022

30. Quality of life in breast cancer patients with cancer treatment-related cardiac dysfunction: a qualitative study

Author

Koop, Y., Zadelhof, N.M van, Maas, A.H.E.M., Atsma, F., El Messaoudi, S., Vermeulen, H., Koop, Y., Zadelhof, N.M van, Maas, A.H.E.M., Atsma, F., El Messaoudi, S., and Vermeulen, H.

Abstract

Contains fulltext : 251384.pdf (Publisher’s version ) (Open Access), BACKGROUND: Although improved breast cancer (BC) treatment has decreased mortality, these anti-cancer regimens may have serious cardiovascular side effects that affect patients' long-term prognosis and quality of life (QoL). BC patients with cancer treatment-related cardiac dysfunction (CTRCD) can suffer from a variety of symptoms, such as dyspnoea and fatigue. The impact of CTRCD after BC treatment on patients' daily life has not been qualitatively explored yet. AIMS: This study aims to explore the influence of CTRCD on QoL of women with BC, as defined by the concept of positive health. Second, we aim to evaluate the personal experience with cardiac surveillance during the BC trajectory. METHODS AND RESULTS: A qualitative study with semi-structured interviews was conducted and thematically analysed to explore the QoL and healthcare experiences of BC patients with CTRCD. Twelve patients participated in this study. Five themes are selected in response to the study objective: (i) patients: overwhelming fatigue, (ii) patients: mental burden of anxiety, (iii) social setting: lack of understanding and acceptance, (iv) medical specialists: lack of knowledge and acknowledgement, and (v) patients: need for personalized care. CONCLUSION: This study identified core components of the impact CTRCD has on the QoL of BC patients. Patients experienced an increased health-related burden due to CTRCD, affecting their physical, social, and psychosocial well-being. Healthcare experiences were largely affected by a lack of acknowledgement and professional communication. Patients underlined the need for personalized care during follow-up.

Published
2022

31. Right atrial and ventricular strain detects subclinical changes in right ventricular function in precapillary pulmonary hypertension

Author

MS Radiologie, Circulatory Health, CCU Cardiologie, Team Medisch, Vos, J. L., Leiner, T., van Dijk, A. P.J., van der Zwaan, H. B., Sieswerda, G. Tj, Snijder, R. J., Post, M. C., Vonk, M. C., van Leuven, S., Vart, P., Snoeren, M., Hirsch, A., El Messaoudi, S., Nijveldt, R., Driessen, M. M.P., MS Radiologie, Circulatory Health, CCU Cardiologie, Team Medisch, Vos, J. L., Leiner, T., van Dijk, A. P.J., van der Zwaan, H. B., Sieswerda, G. Tj, Snijder, R. J., Post, M. C., Vonk, M. C., van Leuven, S., Vart, P., Snoeren, M., Hirsch, A., El Messaoudi, S., Nijveldt, R., and Driessen, M. M.P.

Published
2022

34. ESICM LIVES 2016: part one: Milan, Italy. 1-5 October 2016

Author

Bos, L., Schouten, L., van Vught, L., Wiewel, M., Ong, D., Cremer, O., Artigas, A., Martin-Loeches, I., Hoogendijk, A., van der Poll, T., Horn, J., Juffermans, N., Schultz, M., de Prost, N., Pham, T., Carteaux, G., Dessap, A. Mekontso, Brun-Buisson, C., Fan, E., Bellani, G., Laffey, J., Mercat, A., Brochard, L., Maitre, B., Howells, P. A., Thickett, D. R., Knox, C., Park, D. P., Gao, F., Tucker, O., Whitehouse, T., McAuley, D. F., Perkins, G. D., Pham, T., Laffey, J., Bellani, G., Fan, E., Pisani, L., Roozeman, J. P., Simonis, F. D., Giangregorio, A., Schouten, L. R., Van der Hoeven, S. M., Horn, J., Neto, A. Serpa, Festic, E., Dondorp, A. M., Grasso, S., Bos, L. D., Schultz, M. J., Koster-Brouwer, M., Verboom, D., Scicluna, B., van de Groep, K., Frencken, J., Schultz, M., van der Poll, T., Bonten, M., Cremer, O., Ko, J. I., Kim, K. S., Suh, G. J., Kwon, W. Y., Kim, K., Shin, J. H., Ranzani, O. T., Prina, E., Menendez, R., Ceccato, A., Mendez, R., Cilloniz, C., Gabarrus, A., Ferrer, M., Torres, A., Urbano, A., Zhang, L. A., Swigon, D., Pike, F., Parker, R. S., Clermont, G., Scheer, C., Kuhn, S. O., Modler, A., Vollmer, M., Fuchs, C., Hahnenkamp, K., Rehberg, S., Gründling, M., Taggu, A., Darang, N., Öveges, N., László, I., Tánczos, K., Németh, M., Lebák, G., Tudor, B., Érces, D., Kaszaki, J., Huber, W., Trásy, D., Molnár, Z., Ferrara, G., Edul, V. S. Kanoore, Canales, H. S., Martins, E., Canullán, C., Murias, G., Pozo, M. O., Eguillor, J. F. Caminos, Buscetti, M. G., Ince, C., Dubin, A., Aya, H. D., Rhodes, A., Fletcher, N., Grounds, R. M., Cecconi, M., Jacquet-Lagrèze, M., Riche, M., Schweizer, R., Portran, P., Fornier, W., Lilot, M., Neidecker, J., Fellahi, J. L., Escoresca-Ortega, A., Gutiérrez-Pizarraya, A., Charris-Castro, L., Corcia-Palomo, Y., Fernandez-Delgado, E., Garnacho-Montero, J., Roger, C., Muller, L., Elotmani, L., Lipman, J., Lefrant, J. Y., Roberts, J. A., Muñoz-Bermúdez, R., Samper, M., Climent, C., Vasco, F., Sara, V., Luque, S., Campillo, N., Cerrato, S. Grau, Masclans, J. R., Alvarez-Lerma, F., Brugger, S. Carvalho, Jimenez, G. Jimenez, Torner, M. Miralbés, Cabello, J. Trujillano, Garrido, B. Balsera, Casals, X. Nuvials, Gaite, F. Barcenilla, Vidal, M. Vallverdú, Martínez, M. Palomar, Gusarov, V., Shilkin, D., Dementienko, M., Nesterova, E., Lashenkova, N., Kuzovlev, A., Zamyatin, M., Demoule, A., Carreira, S., Lavault, S., Palancca, O., Morawiec, E., Mayaux, J., Arnulf, I., Similowski, T., Rasmussen, B. S., Maltesen, R. G., Hanifa, M., Pedersen, S., Kristensen, S. R., Wimmer, R., Panigada, M., Bassi, G. Li, Ranzani, O. T., Kolobow, T., Zanella, A., Cressoni, M., Berra, L., Parrini, V., Kandil, H., Salati, G., Livigni, S., Amatu, A., Andreotti, A., Tagliaferri, F., Moise, G., Mercurio, G., Costa, A., Vezzani, A., Lindau, S., Babel, J., Cavana, M., Consonni, D., Pesenti, A., Gattinoni, L., Torres, A., Mansouri, P., Zand, F., Zahed, L., Dehghanrad, F., Bahrani, M., Ghorbani, M., Cambiaghi, B., Moerer, O., Mauri, T., Kunze-Szikszay, N., Ritter, C., Pesenti, A., Quintel, M., Vilander, L. M., Kaunisto, M. A., Vaara, S. T., Pettilä, V., Mulier, J. L. G. Haitsma, Rozemeijer, S., Spoelstra-de Man, A. M. E., Elbers, P. E., Tuinman, P. R., de Waard, M. C., Oudemans-van Straaten, H. M., Liberatore, A. M. A., Souza, R. B., Martins, A. M. C. R. P. F., Vieira, J. C. F., Koh, I. H. J., Martínez, M. Galindo, Sánchez, R. Jiménez, Gascón, L. Martínez, Mulero, M. D. Rodríguez, Freire, A. Ortín, Muñoz, A. Ojados, Acebes, S. Rebollo, Martínez, Á. Fernández, Aliaga, S. Moreno, Para, L. Herrera, Payá, J. Murcia, Mulero, F. Rodríguez, Guerci, P., Ince, Y., Heeman, P., Ergin, B., Ince, C., Uz, Z., Massey, M., Ince, Y., Papatella, R., Bulent, E., Guerci, P., Toraman, F., Ince, C., Longbottom, E. R., Torrance, H. D., Owen, H. C., Hinds, C. J., Pearse, R. M., O’Dywer, M. J., Trogrlic, Z., van der Jagt, M., Lingsma, H., Ponssen, H. H., Schoonderbeek, J. F., Schreiner, F., Verbrugge, S. J., Duran, S., van Achterberg, T., Bakker, J., Gommers, D. A. M. P. J., Ista, E., Krajčová, A., Waldauf, P., Duška, F., Shah, A., Roy, N., McKechnie, S., Doree, C., Fisher, S., Stanworth, S. J., Jensen, J. F., Overgaard, D., Bestle, M. H., Christensen, D. F., Egerod, I., Pivkina, A., Gusarov, V., Zhivotneva, I., Pasko, N., Zamyatin, M., Jensen, J. F., Egerod, I., Bestle, M. H., Christensen, D. F., Alklit, A., Hansen, R. L., Knudsen, H., Grode, L. B., Overgaard, D., Hravnak, M., Chen, L., Dubrawski, A., Clermont, G., Pinsky, M. R., Parry, S. M., Knight, L. D., Connolly, B. C., Baldwin, C. E., Puthucheary, Z. A., Denehy, L., Hart, N., Morris, P. E., Mortimore, J., Granger, C. L., Jensen, H. I., Piers, R., Van den Bulcke, B., Malmgren, J., Metaxa, V., Reyners, A. K., Darmon, M., Rusinova, K., Talmor, D., Meert, A. P., Cancelliere, L., Zubek, L., Maia, P., Michalsen, A., Decruyenaere, J., Kompanje, E., Vanheule, S., Azoulay, E., Vansteelandt, S., Benoit, D., Van den Bulcke, B., Piers, R., Jensen, H. I., Malmgren, J., Metaxa, V., Reyners, A. K., Darmon, M., Rusinova, K., Talmor, D., Meert, A. P., Cancelliere, L., Zubek, L., Maia, P., Michalsen, A., Decruyenaere, J., Kompanje, E., Vanheule, S., Azoulay, E., Vansteelandt, S., Benoit, D., Ryan, C., Dawson, D., Ball, J., Noone, K., Aisling, B., Prudden, S., Ntantana, A., Matamis, D., Savvidou, S., Giannakou, M., Gouva, M., Nakos, G., Koulouras, V., Aron, J., Lumley, G., Milliken, D., Dhadwal, K., McGrath, B. A., Lynch, S. J., Bovento, B., Sharpe, G., Grainger, E., Pieri-Davies, S., Wallace, S., McGrath, B., Lynch, S. J., Bovento, B., Grainger, E., Pieri-Davies, S., Sharpe, G., Wallace, S., Jung, M., Cho, J., Park, H., Suh, G., Kousha, O., Paddle, J., Gripenberg, L. Gamrin, Rehal, M. Sundström, Wernerman, J., Rooyackers, O., de Grooth, H. J., Choo, W. P., Spoelstra-de Man, A. M., Swart, E. L., Oudemans-van Straaten, H. M., Talan, L., Güven, G., Altıntas, N. D., Padar, M., Uusvel, G., Starkopf, L., Starkopf, J., Blaser, A. Reintam, Kalaiselvan, M. S., Arunkumar, A. S., Renuka, M. K., Shivkumar, R. L., Volbeda, M., ten Kate, D., Hoekstra, M., van der Maaten, J. M., Nijsten, M. W., Komaromi, A., Rooyackers, O., Wernerman, J., Norberg, Å., Smedberg, M., Mori, M., Pettersson, L., Norberg, Å., Rooyackers, O., Wernerman, J., Theodorakopoulou, M., Christodoulopoulou, T., Diamantakis, A., Frantzeskaki, F., Kontogiorgi, M., Chrysanthopoulou, E., Lygnos, M., Diakaki, C., Armaganidis, A., Gundogan, K., Dogan, E., Coskun, R., Muhtaroglu, S., Sungur, M., Ziegler, T., Guven, M., Kleyman, A., Khaliq, W., Andreas, D., Singer, M., Meierhans, R., Schuepbach, R., De Brito-Ashurst, I., Zand, F., Sabetian, G., Nikandish, R., Hagar, F., Masjedi, M., Maghsudi, B., Vazin, A., Ghorbani, M., Asadpour, E., Kao, K. C., Chiu, L. C., Hung, C. Y., Chang, C. H., Li, S. H., Hu, H. C., El Maraghi, S., Ali, M., Rageb, D., Helmy, M., Marin-Corral, J., Vilà, C., Masclans, J. R., Vàzquez, A., Martín-Loeches, I., Díaz, E., Yébenes, J. C., Rodriguez, A., Álvarez-Lerma, F., Varga, N., Cortina-Gutiérrez, A., Dono, L., Martínez-Martínez, M., Maldonado, C., Papiol, E., Pérez-Carrasco, M., Ferrer, R., Nweze, K., Morton, B., Welters, I., Houard, M., Voisin, B., Ledoux, G., Six, S., Jaillette, E., Nseir, S., Romdhani, S., Bouneb, R., Loghmari, D., Aicha, N. Ben, Ayachi, J., Meddeb, K., Chouchène, I., Khedher, A., Boussarsar, M., Chan, K. S., Yu, W. L., Marin-Corral, J., Vilà, C., Masclans, J. R., Nolla, J., Vidaur, L., Bonastre, J., Suberbiola, B., Guerrero, J. E., Rodriguez, A., Coll, N. Ramon, Jiménez, G. Jiménez, Brugger, S. Carvalho, Calero, J. Codina, Garrido, B. Balsera, García, M., Martínez, M. Palomar, Vidal, M. Vallverdú, de la Torre, M. C., Vendrell, E., Palomera, E., Güell, E., Yébenes, J. C., Serra-Prat, M., Bermejo-Martín, J. F., Almirall, J., Tomas, E., Escoval, A., Froe, F., Pereira, M. H. Vitoria, Velez, N., Viegas, E., Filipe, E., Groves, C., Reay, M., Chiu, L. C., Hu, H. C., Hung, C. Y., Chang, C. H., Li, S. H., Kao, K. C., Ballin, A., Facchin, F., Sartori, G., Zarantonello, F., Campello, E., Radu, C. M., Rossi, S., Ori, C., Simioni, P., Umei, N., Shingo, I., Santos, A. C., Candeias, C., Moniz, I., Marçal, R., e Silva, Z. Costa, Ribeiro, J. M., Georger, J. F., Ponthus, J. P., Tchir, M., Amilien, V., Ayoub, M., Barsam, E., Martucci, G., Panarello, G., Tuzzolino, F., Capitanio, G., Ferrazza, V., Carollo, T., Giovanni, L., Arcadipane, A., Sánchez, M. López, González-Gay, M. A., Díaz, F. J. Llorca, López, M. I. Rubio, Zogheib, E., Villeret, L., Nader, J., Bernasinski, M., Besserve, P., Caus, T., Dupont, H., Morimont, P., Habran, S., Hubert, R., Desaive, T., Blaffart, F., Janssen, N., Guiot, J., Pironet, A., Dauby, P., Lambermont, B., Zarantonello, F., Ballin, A., Facchin, F., Sartori, G., Campello, E., Pettenuzzo, T., Citton, G., Rossi, S., Simioni, P., Ori, C., Kirakli, C., Ediboglu, O., Ataman, S., Yarici, M., Tuksavul, F., Keating, S., Gibson, A., Gilles, M., Dunn, M., Price, G., Young, N., Remeta, P., Bishop, P., Zamora, M. D. Fernández, Muñoz-Bono, J., Curiel-Balsera, E., Aguilar-Alonso, E., Hinojosa, R., Gordillo-Brenes, A., Arboleda-Sánchez, J. A., Skorniakov, I., Vikulova, D., Whiteley, C., Shaikh, O., Jones, A., Ostermann, M., Forni, L., Scott, M., Sahatjian, J., Linde-Zwirble, W., Hansell, D., Laoveeravat, P., Srisawat, N., Kongwibulwut, M., Peerapornrattana, S., Suwachittanont, N., Wirotwan, T. O., Chatkaew, P., Saeyub, P., Latthaprecha, K., Tiranathanagul, K., Eiam-ong, S., Kellum, J. A., Berthelsen, R. E., Perner, A., Jensen, A. E. K., Jensen, J. U., Bestle, M. H., Gebhard, D. J., Price, J., Kennedy, C. E., Akcan-Arikan, A., Liberatore, A. M. A., Souza, R. B., Martins, A. M. C. R. P. F., Vieira, J. C. F., Kang, Y. R., Nakamae, M. N., Koh, I. H. J., Hamed, K., Khaled, M. M., Soliman, R. Aly, Mokhtar, M. Sherif, Seller-Pérez, G., Arias-Verdú, D., Llopar-Valdor, E., De-Diós-Chacón, I., Quesada-García, G., Herrera-Gutierrez, M. E., Hafes, R., Carroll, G., Doherty, P., Wright, C., Vera, I. G. Guerra, Ralston, M., Gemmell, M. L., MacKay, A., Black, E., Wright, C., Docking, R. I., Appleton, R., Ralston, M. R., Gemmell, L., Appleton, R., Wright, C., Docking, R. I., Black, E., Mackay, A., Rozemeijer, S., Mulier, J. L. G. Haitsma, Röttgering, J. G., Elbers, P. W. G., Spoelstra-de Man, A. M. E., Tuinman, P. R., de Waard, M. C., Oudemans-van Straaten, H. M., Mejeni, N., Nsiala, J., Kilembe, A., Akilimali, P., Thomas, G., Egerod, I., Andersson, A. E., Fagerdahl, A. M., Knudsen, V., Meddeb, K., Cheikh, A. Ben, Hamdaoui, Y., Ayachi, J., Guiga, A., Fraj, N., Romdhani, S., Sma, N., Bouneb, R., Chouchene, I., Khedher, A., Bouafia, N., Boussarsar, M., Amirian, A., Ziaian, B., Masjedi, M., Fleischmann, C., Thomas-Rueddel, D. O., Schettler, A., Schwarzkopf, D., Stacke, A., Reinhart, K., Filipe, E., Escoval, A., Martins, A., Sousa, P., Velez, N., Viegas, E., Tomas, E., Snell, G., Matsa, R., Paary, T. T. S., Kalaiselvan, M. S., Cavalheiro, A. M., Rocha, L. L., Vallone, C. S., Tonilo, A., Lobato, M. D. S., Malheiro, D. T., Sussumo, G., Lucino, N. M., Zand, F., Rosenthal, V. D., Masjedi, M., Sabetian, G., Maghsudi, B., Ghorbani, M., Dashti, A. Sanaei, Yousefipour, A., Goodall, J. R., Williamson, M., Tant, E., Thomas, N., Balci, C., Gonen, C., Haftacı, E., Gurarda, H., Karaca, E., Paldusová, B., Zýková, I., Šímová, D., Houston, S., D’Antona, L., Lloyd, J., Garnelo-Rey, V., Sosic, M., Sotosek-Tokmazic, V., Kuharic, J., Antoncic, I., Dunatov, S., Sustic, A., Chong, C. T., Sim, M., Lyovarin, T., Díaz, F. M. Acosta, Galdó, S. Narbona, Garach, M. Muñoz, Romero, O. Moreno, Bailón, A. M. Pérez, Pinel, A. Carranza, Colmenero, M., Gritsan, A., Gazenkampf, A., Korchagin, E., Dovbish, N., Lee, R. M., Lim, M. P. P., Chong, C. T., Lim, B. C. L., See, J. J., Assis, R., Filipe, F., Lopes, N., Pessoa, L., Pereira, T., Catorze, N., Aydogan, M. S., Aldasoro, C., Marchio, P., Jorda, A., Mauricio, M. D., Guerra-Ojeda, S., Gimeno-Raga, M., Colque-Cano, M., Bertomeu-Artecero, A., Aldasoro, M., Valles, S. L., Tonon, D., Triglia, T., Martin, J. C., Alessi, M. C., Bruder, N., Garrigue, P., Velly, L., Spina, S., Scaravilli, V., Marzorati, C., Colombo, E., Savo, D., Vargiolu, A., Cavenaghi, G., Citerio, G., Andrade, A. H. V., Bulgarelli, P., Araujo, J. A. P., Gonzalez, V., Souza, V. A., Costa, A., Massant, C., Filho, C. A. C. Abreu, Morbeck, R. A., Burgo, L. E., van Groenendael, R., van Eijk, L. T., Leijte, G. P., Koeneman, B., Kox, M., Pickkers, P., García-de la Torre, A., de la Torre-Prados, M., Fernández-Porcel, A., Rueda-Molina, C., Nuevo-Ortega, P., Tsvetanova-Spasova, T., Cámara-Sola, E., García-Alcántara, A., Salido-Díaz, L., Liao, X., Feng, T., Zhang, J., Cao, X., Wu, Q., Xie, Z., Li, H., Kang, Y., Winkler, M. S., Nierhaus, A., Mudersbach, E., Bauer, A., Robbe, L., Zahrte, C., Schwedhelm, E., Kluge, S., Zöllner, C., Morton, B., Mitsi, E., Pennington, S. H., Reine, J., Wright, A. D., Parker, R., Welters, I. D., Blakey, J. D., Rajam, G., Ades, E. W., Ferreira, D. M., Wang, D., Kadioglu, A., Gordon, S. B., Koch, R., Kox, M., Rahamat-Langedoen, J., Schloesser, J., de Jonge, M., Pickkers, P., Bringue, J., Guillamat-Prats, R., Torrents, E., Martinez, M. L., Camprubí-Rimblas, M., Artigas, A., Blanch, L., Park, S. Y., Park, Y. B., Song, D. K., Shrestha, S., Park, S. H., Koh, Y., Park, M. J., Hong, C. W., Lesur, O., Coquerel, D., Sainsily, X., Cote, J., Söllradl, T., Murza, A., Dumont, L., Dumaine, R., Grandbois, M., Sarret, P., Marsault, E., Salvail, D., Auger-Messier, M., Chagnon, F., Lauretta, M. P., Greco, E., Dyson, A., Singer, M., Preau, S., Ambler, M., Sigurta, A., Saeed, S., Singer, M., Sarıca, L. Topcu, Zibandeh, N., Genc, D., Gul, F., Akkoc, T., Kombak, E., Cinel, L., Akkoc, T., Cinel, I., Pollen, S. J., Arulkumaran, N., Singer, M., Torrance, H. D., Longbottom, E. R., Warnes, G., Hinds, C. J., Pennington, D. J., Brohi, K., O’Dwyer, M. J., Kim, H. Y., Na, S., Kim, J., Chang, Y. F., Chao, A., Shih, P. Y., Lee, C. T., Yeh, Y. C., Chen, L. W., Adriaanse, M., Trogrlic, Z., Ista, E., Lingsma, H., Rietdijk, W., Ponssen, H. H., Schoonderbeek, J. F., Schreiner, F., Verbrugge, S. J., Duran, S., Gommers, D. A. M. P. J., van der Jagt, M., Funcke, S., Sauerlaender, S., Saugel, B., Pinnschmidt, H., Reuter, D. A., Nitzschke, R., Perbet, S., Biboulet, C., Lenoire, A., Bourdeaux, D., Pereira, B., Plaud, B., Bazin, J. E., Sautou, V., Mebazaa, A., Constantin, J. M., Legrand, M., Boyko, Y., Jennum, P., Nikolic, M., Oerding, H., Holst, R., Toft, P., Nedergaard, H. K., Haberlandt, T., Jensen, H. I., Toft, P., Park, S., Kim, S., Cho, Y. J., Lim, Y. J., Chan, A., Tang, S., Nunes, S. L., Forsberg, S., Blomqvist, H., Berggren, L., Sörberg, M., Sarapohja, T., Wickerts, C. J., Hofhuis, J. G. M., Rose, L., Blackwood, B., Akerman, E., Mcgaughey, J., Egerod, I., Fossum, M., Foss, H., Georgiou, E., Graff, H. J., Kalafati, M., Sperlinga, R., Schafer, A., Wojnicka, A. G., Spronk, P. E., Zand, F., Khalili, F., Afshari, R., Sabetian, G., Masjedi, M., Maghsudi, B., Khodaei, H. Haddad, Javadpour, S., Petramfar, P., Nasimi, S., Vazin, A., Ziaian, B., Tabei, H., Gunther, A., Hansen, J. O., Sackey, P., Storm, H., Bernhardsson, J., Sundin, Ø., Bjärtå, A., Bienert, A., Smuszkiewicz, P., Wiczling, P., Przybylowski, K., Borsuk, A., Trojanowska, I., Matysiak, J., Kokot, Z., Paterska, M., Grzeskowiak, E., Messina, A., Bonicolini, E., Colombo, D., Moro, G., Romagnoli, S., De Gaudio, A. R., Corte, F. Della, Romano, S. M., Silversides, J. A., Major, E., Mann, E. E., Ferguson, A. J., Mcauley, D. F., Marshall, J. C., Blackwood, B., Fan, E., Diaz-Rodriguez, J. A., Silva-Medina, R., Gomez-Sandoval, E., Gomez-Gonzalez, N., Soriano-Orozco, R., Gonzalez-Carrillo, P. L., Hernández-Flores, M., Pilarczyk, K., Lubarksi, J., Wendt, D., Dusse, F., Günter, J., Huschens, B., Demircioglu, E., Jakob, H., Palmaccio, A., Dell’Anna, A. M., Grieco, D. L., Torrini, F., Iaquaniello, C., Bongiovanni, F., Antonelli, M., Toscani, L., Antonakaki, D., Bastoni, D., Aya, H. D., Rhodes, A., Cecconi, M., Jozwiak, M., Depret, F., Teboul, J. L., Alphonsine, J., Lai, C., Richard, C., Monnet, X., László, I., Demeter, G., Öveges, N., Tánczos, K., Németh, M., Trásy, D., Kertmegi, I., Érces, D., Tudor, B., Kaszaki, J., Molnár, Z., Hasanin, A., Lotfy, A., El-adawy, A., Nassar, H., Mahmoud, S., Abougabal, A., Mukhtar, A., Quinty, F., Habchi, S., Luzi, A., Antok, E., Hernandez, G., Lara, B., Enberg, L., Ortega, M., Leon, P., Kripper, C., Aguilera, P., Kattan, E., Bakker, J., Huber, W., Lehmann, M., Sakka, S., Bein, B., Schmid, R. M., Preti, J., Creteur, J., Herpain, A., Marc, J., Zogheib, E., Trojette, F., Bar, S., Kontar, L., Titeca, D., Richecoeur, J., Gelee, B., Verrier, N., Mercier, R., Lorne, E., Maizel, J., Dupont, H., Slama, M., Abdelfattah, M. E., Eladawy, A., Elsayed, M. A. Ali, Mukhtar, A., Montenegro, A. Pedraza, Zepeda, E. Monares, Granillo, J. Franco, Sánchez, J. S. Aguirre, Alejo, G. Camarena, Cabrera, A. Rugerio, Montoya, A. A. Tanaka, Lee, C., Hatib, F., Cannesson, M., Theerawit, P., Morasert, T., Sutherasan, Y., Zani, G., Mescolini, S., Diamanti, M., Righetti, R., Scaramuzza, A., Papetti, M., Terenzoni, M., Gecele, C., Fusari, M., Hakim, K. A., Chaari, A., Ismail, M., Elsaka, A. H., Mahmoud, T. M., Bousselmi, K., Kauts, V., Casey, W. F., Hutchings, S. D., Naumann, D., Wendon, J., Watts, S., Kirkman, E., Jian, Z., Buddi, S., Lee, C., Settels, J., Hatib, F., Pinsky, M. R., Bertini, P., Guarracino, F., Trepte, C., Richter, P., Haas, S. A., Eichhorn, V., Kubitz, J. C., Reuter, D. A., Soliman, M. S., Hamimy, W. I., Fouad, A. Z., Mukhtar, A. M., Charlton, M., Tonks, L., Mclelland, L., Coats, T. J., Thompson, J. P., Sims, M. R., Williams, D., Roushdy, D. Z., Soliman, R. A., Nahas, R. A., Arafa, M. Y., Hung, W. T., Chiang, C. C., Huang, W. C., Lin, K. C., Lin, S. C., Cheng, C. C., Kang, P. L., Wann, S. R., Mar, G. Y., Liu, C. P., Carranza, M. Lopez, Fernandez, H. Sancho, Roman, J. A. Sanchez, Lucena, F., Garcia, A. Campanario, Vazquez, A. Loza, Serrano, A. Lesmes, Moreira, L. Sayagues, Vidal-Perez, R., Herranz, U. Anido, Acuna, J. M. Garcia, Gil, C. Pena, Allut, J. L. Garcia, Sedes, P. Rascado, Lopez, C. Martin, Paz, E. Saborido, Rodriguez, C. Galban, Gonzalez-Juanatey, J. R., Vallejo-Baez, A., de la Torre-Prados, M. V., Nuevo-Ortega, P., Fernández-Porcel, A., Cámara-Sola, E., Tsvetanova-Spasova, T., Rueda-Molina, C., Salido-Díaz, L., García-Alcántara, A., Aron, J., Marharaj, R., Gervasio, K., Bottiroli, M., Mondino, M., De Caria, D., Calini, A., Montrasio, E., Milazzo, F., Gagliardone, M. P., Vallejo-Báez, A., de la Torre-Prados, M. V., Nuevo-Ortega, P., Fernández-Porcel, A., Cámara-Sola, E., Tsvetanova-Spasova, T., Rueda-Molina, C., Salido-Díaz, L., García-Alcántara, A., Moreira, L. Sayagues, Vidal-Perez, R., Anido, U., Gil, C. Pena, Acuna, J. M. Garcia, Sedes, P. Rascado, Lopez, C. Martin, Paz, E. Saborido, Allut, J. L. Garcia, Rodriguez, C. Galban, Gonzalez-Juanatey, J. R., Hamdaoui, Y., Khedher, A., Cheikh-Bouhlel, M., Ayachi, J., Meddeb, K., Sma, N., Fraj, N., Aicha, N. Ben, Romdhani, S., Bouneb, R., Chouchene, I., Boussarsar, M., Dela Cruz, M. P. R. D. L., Bernardo, J. M., Galfo, F., Dyson, A., Singer, M., Marino, A., Dyson, A., Singer, M., Chao, C. C., Hou, P., Huang, W. C., Hung, C. C., Chiang, C. H., Hung, W. T., Lin, K. C., Lin, S. C., Liou, Y. J., Hung, S. M., Lin, Y. S., Cheng, C. C., Kuo, F. Y., Chiou, K. R., Chen, C. J., Yan, L. S., Liu, C. Y., Wang, H. H., Kang, P. L., Chen, H. L., Ho, C. K., Mar, G. Y., Liu, C. P., Grewal, S., Gopal, S., Corbett, C., Wilson, A., Capps, J., Ayoub, W., Lomas, A., Ghani, S., Moore, J., Atkinson, D., Sharman, M., Swinnen, W., Pauwels, J., Mignolet, K., Pannier, E., Koch, A., Sarens, T., Temmerman, W., Elmenshawy, A. M., Fayed, A. M., Elboriuny, M., Hamdy, E., Zakaria, E., Falk, A. C., Petosic, A., Olafsen, K., Wøien, H., Flaatten, H., Sunde, K., Agra, J. J. Cáceres, Cabrera, J. L. Santana, Santana, J. D. Martín, Alzola, L. Melián, Pérez, H. Rodríguez, Pires, T. Castro, Calderón, H., Pereira, A., Castro, S., Granja, C., Norkiene, I., Urbanaviciute, I., Kezyte, G., Ringaitiene, D., Jovaisa, T., Vogel, G., Johansson, U. B., Sandgren, A., Svensen, C., Joelsson-Alm, E., Leite, M. A., Murbach, L. D., Osaku, E. F., Costa, C. R. L. M., Pelenz, M., Neitzke, N. M., Moraes, M. M., Jaskowiak, J. L., Silva, M. M. M., Zaponi, R. S., Abentroth, L. R. L., Ogasawara, S. M., Jorge, A. C., Duarte, P. A. D., Murbach, L. D., Leite, M. A., Osaku, E. F., Barreto, J., Duarte, S. T., Taba, S., Miglioranza, D., Gund, D. P., Lordani, C. F., Costa, C. R. L. M., Ogasawara, S. M., Jorge, A. C., Duarte, P. A. D., Vollmer, H., Gager, M., Waldmann, C., Mazzeo, A. T., Tesio, R., Filippini, C., Vallero, M. E., Giolitti, C., Caccia, S., Medugno, M., Tenaglia, T., Rosato, R., Mastromauro, I., Brazzi, L., Terragni, P. P., Urbino, R., Fanelli, V., Ranieri, V. M., Mascia, L., Ballantyne, J., Paton, L., Mackay, A., Perez-Teran, P., Roca, O., Ruiz-Rodriguez, J. C., Zapatero, A., Serra, J., Masclans, J. R., Bianzina, S., Cornara, P., Rodi, G., Tavazzi, G., Pozzi, M., Iotti, G. A., Mojoli, F., Braschi, A., Vishnu, A., Buche, D., Pande, R., Moolenaar, D. L. J., Bakhshi-Raiez, F., Dongelmans, D. A., de Keizer, N. F., de Lange, D. W., Fernández, I. Fuentes, Baño, D. Martínez, Moreno, J. L. Buendía, Rubio, R. Jara, Scott, J., Phelan, D., Morely, D., O’Flynn, J., Stapleton, P., Lynch, M., Marsh, B., Carton, E., O’Loughlin, C., Cheng, K. C., Sung, M. I., Elghonemi, M. O., Saleh, M. H., Meyhoff, T. S., Krag, M., Hjortrup, P. B., Perner, A., Møller, M. H., Öhman, T., Sigmundsson, T., Redondo, E., Hallbäck, M., Suarez-Sipmann, F., Björne, H., Sander, C. Hällsjö, Cressoni, M., Chiumello, D., Chiurazzi, C., Brioni, M., Algieri, I., Guanziroli, M., Vergani, G., Tonetti, T., Tomic, I., Colombo, A., Crimella, F., Carlesso, E., Colombo, A., Gasparovic, V., Gattinoni, L., El-Sherif, R., Al-Basser, M. Abd, Raafat, A., El-Sherif, A., Simonis, F. D., Schouten, L. R. A., Cremer, O. L., Ong, D. S. Y., Amoruso, G., Cinnella, G., Schultz, M. J., Bos, L. D. J., Huber, W., Schmidle, P., Findeisen, M., Hoppmann, P., Jaitner, J., Brettner, F., Schmid, R. M., Lahmer, T., Festic, E., Rajagopalan, G., Bansal, V., Frank, R., Hinds, R., Levitt, J., Siddiqui, S., Gilbert, J. P., Sim, K., Wang, C. H., Hu, H. C., Li, I. J., Tang, W. R., Kao, K. C., Persona, P., De Cassai, A., Franco, M., Facchin, F., Ori, C., Rossi, S., Goffi, A., Li, S. H., Hu, H. C., Chiu, L. C., Hung, C. Y., Chang, C. H., Kao, K. C., Ruiz, B. Llorente, Varas, J. Lujan, Montero, R. Molina, Delgado, C. Pintado, Navarrete, O., Mezquita, M. Vazquez, Peces, E. Alonso, Nakamura, M. A. M., Hajjar, L. A., Galas, F. R. B. G., Ortiz, T. A., Amato, M. B. P., Bitker, L., Costes, N., Le Bars, D., Lavenne, F., Mojgan, D., Richard, J. C., Chiurazzi, C., Cressoni, M., Massari, D., Guanziroli, M., Vergani, G., Gotti, M., Brioni, M., Algieri, I., Cadringher, P., Tonetti, T., Chiumello, D., Gattinoni, L., Zerman, A., Türkoğlu, M., Arık, G., Yıldırım, F., Güllü, Z., Kara, I., Boyacı, N., Aydoğan, B. Basarık, Gaygısız, Ü., Gönderen, K., Aygencel, G., Aydoğdu, M., Ülger, Z., Gürsel, G., Riera, J., Toral, C. Maldonado, Mazo, C., Martínez, M., Baldirà, J., Lagunes, L., Roman, A., Deu, M., Rello, J., Levine, D. J., Mohus, R. M., Askim, Å., Paulsen, J., Mehl, A., Dewan, A. T., Damås, J. K., Solligård, E., Åsvold, B. O., Paulsen, J., Askim, Å., Mohus, R. M., Mehl, A., DeWan, A., Solligård, E., Damås, J. K., Åsvold, B. O., Aktepe, O., Kara, A., Yeter, H., Topeli, A., Norrenberg, M., Devroey, M., Khader, H., Preiser, J. C., Tang, Z., Qiu, C., Tong, L., Cai, C., Theodorakopoulou, M., Diamantakis, A., Kontogiorgi, M., Chrysanthopoulou, E., Christodoulopoulou, T., Frantzeskaki, F., Lygnos, M., Apostolopoulou, O., Armaganidis, A., Moon, J. Y., Park, M. R., Kwon, I. S., Chon, G. R., Ahn, J. Y., Kwon, S. J., Chang, Y. J., Lee, J. Y., Yoon, S. Y., Lee, J. W., Kostalas, M., Mckinlay, J., Kooner, G., Dudas, G., Horton, A., Kerr, C., Karanjia, N., Creagh-Brown, B., Altintas, N. D., Izdes, S., Keremoglu, O., Alkan, A., Neselioglu, S., Erel, O., Tardif, N., Gustafsson, T., Rooyackers, O., MacEachern, K. N., Traille, M., Bromberg, I., Lapinsky, S. E., Moore, M. J., Tang, Z., Cai, C., Tong, L., García-Garmendia, J. L., Villarrasa-Clemente, F., Maroto-Monserrat, F., Rufo-Tejeiro, O., Jorge-Amigo, V., Sánchez-Santamaría, M., Colón-Pallarés, C., Barrero-Almodóvar, A., Gallego-Lara, S., Anthon, C. T., Müller, R. B., Haase, N., Møller, K., Hjortrup, P. B., Wetterslev, J., Perner, A., Nakanishi, M., Kuriyama, A., Fukuoka, T., Abd el Halim, M. A., Elsaid hafez, M. H., Moktar, A. M., Eladawy, A., Elazizy, H. M., Hakim, K. Abdel, Chaari, A., Elbahr, M., Ismail, M., Mahmoud, T., Kauts, V., Bousselmi, K., Khalil, E., Casey, W., Zaky, S. H., Rizk, A., Elghonemi, M. O., Ahmed, R., Vieira, J. C. F., Souza, R. B., Liberatore, A. M. A., Koh, I. H. J., Ospina-Tascón, G. A., Marin, A. F. Garcia, Echeverry, G. J., Bermudez, W. F., Madriñan-Navia, H. J., Valencia, J. D., Quiñonez, E., Marulanda, A., Arango-Dávila, C. A., Bruhn, A., Hernandez, G., De Backer, D., Cortes, D. Orbegozo, Su, F., Vincent, J. L., Creteur, J., Tullo, L., Mirabella, L., Di Molfetta, P., Cinnella, G., Dambrosio, M., Lujan, C. Villavicencio, irigoyen, J. Leache, Cartanya ferré, M., García, R. Carbonell, Mukhtar, A., Ahmed, M., El Ayashi, M., Hasanin, A., Ayman, E., Salem, M., Eladawy, A., Fathy, S., Nassar, H., Zaghlol, A., Arzapalo, M. F. Aguilar, Valsø, Å., Sunde, K., Rustøen, T., Schou-Bredal, I., Skogstad, L., Tøien, K., Padilla, C., Palmeiro, Y., Egbaria, W., Kigli, R., Maertens, B., Blot, K., Blot, S., Santana-Santos, E., dos Santos, E. R., Ferretti-Rebustini, R. E. D. L., dos Santos, R. D. C. C. D. O., Verardino, R. G. S., Bortolotto, L. A., Doyle, A. M., Naldrett, I., Tillman, J., Price, S., Shrestha, S., Pearson, P., Greaves, J., Goodall, D., Berry, A., Richardson, A., Odundo, G. O., Omengo, P., Obonyo, P., Chanzu, N. M., Kleinpell, R., Sarris, S. J., Nedved, P., Heitschmidt, M., Ben-Ghezala, H., Snouda, S., Djobbi, S., Ben-Ghezala, H., Snouda, S., Rose, L., Adhikari, N. K. J., Leasa, D., Fergusson, D., Mckim, D. A., Weblin, J., Tucker, O., McWilliams, D., Doesburg, F., Cnossen, F., Dieperink, W., Bult, W., Nijsten, M. W. N., Galvez-Blanco, G. A., Zepeda, E. Monares, Guzman, C. I. Olvera, Sánchez, J. S. Aguirre, Granillo, J. Franco, Stroud, J. Santos, Thomson, R., Llaurado-Serra, M., Lobo-Civico, A., Pi-Guerrero, M., Blanco-Sanchez, I., Piñol-Tena, A., Paños-Espinosa, C., Alabart-Segura, Y., Coloma-Gomez, B., Fernandez-Blanco, A., Braga-Dias, F., Treso-Geira, M., Valeiras-Valero, A., Martinez-Reyes, L., Sandiumenge, A., Jimenez-Herrera, M. F., Prada, R., Juárez, P., Argandoña, R., Díaz, J. J., Ramirez, C. Sánchez, Saavedra, P., Santana, S. Ruiz, Obukhova, O., Kashiya, S., Kurmukov, I. A., Pronina, A. M., Simeone, P., Puybasset, L., Auzias, G., Coulon, O., Lesimple, B., Torkomian, G., Velly, L., Bienert, A., Bartkowska-Sniatkowska, A., Wiczling, P., Szerkus, O., Siluk, D., Bartkowiak-Wieczorek, J., Rosada-Kurasinska, J., Warzybok, J., Borsuk, A., Kaliszan, R., Grzeskowiak, E., Caballero, C. Hernandez, Roberts, S., Isgro, G., Hall, D., Guillaume, G., Passouant, O., Dumas, F., Bougouin, W., Champigneulle, B., Arnaout, M., Chelly, J., Chiche, J. D., Varenne, O., Mira, J. P., Marijon, E., Cariou, A., Beerepoot, M., Touw, H. R., Parlevliet, K., Boer, C., Elbers, P. W., Tuinman, P. R., Reina, Á. J. Roldán, Palomo, Y. Corcia, Bermúdez, R. Martín, Villén, L. Martín, García, I. Palacios, Izurieta, J. R. Naranjo, Bernal, J. B. Pérez, Jiménez, F. J. Jiménez, Cota-Delgado, F., de la Torre-Prados, M. V., Fernández-Porcel, A., Nuevo-Ortega, P., Cámara-Sola, E., Tsvetanova-Spasova, T., Rueda-Molina, C., Salido-Díaz, L., García-Alcántara, A., Kaneko, T., Tanaka, H., Kamikawa, M., Karashima, R., Iwashita, S., Irie, H., Kasaoka, S., Arola, O., Laitio, R., Saraste, A., Airaksinen, J., Pietilä, M., Hynninen, M., Wennervirta, J., Bäcklund, M., Ylikoski, E., Silvasti, P., Nukarinen, E., Grönlund, J., Harjola, V. P., Niiranen, J., Korpi, K., Varpula, M., Roine, R. O., Laitio, T., Salah, S., Hassen, B. G., Fehmi, A. Mohamed, Kim, S., Hsu, Y. C., Barea-Mendoza, J., García-Fuentes, C., Castillo-Jaramillo, M., Dominguez-Aguado, H., Viejo-Moreno, R., Terceros-Almanza, L., Aznárez, S. Bermejo, Mudarra-Reche, C., Xu, W., Chico-Fernández, M., Montejo-González, J. C., Crewdson, K., Thomas, M., Merghani, M., Fenner, L., Morgan, P., Lockey, D., van Lieshout, E. J., Oomen, B., Binnekade, J. M., Dongelmans, D. A., de Haan, R. J., Juffermans, N. P., Vroom, M. B., Algarte, R., Martínez, L., Sánchez, B., Romero, I., Martínez, F., Quintana, S., Trenado, J., Sheikh, O., Pogson, D., Clinton, R., Riccio, F., Gemmell, L., MacKay, A., Arthur, A., Young, L., Sinclair, A., Markopoulou, D., Venetsanou, K., Filippou, L., Salla, E., Stratouli, S., Alamanos, I., Guirgis, A. H., Rodriguez, R. Gutiérrez, Lorente, M. J. Furones, Guarasa, I. Macias, Ukere, A., Meisner, S., Greiwe, G., Opitz, B., Benten, D., Nashan, B., Fischer, L., Trepte, C. J. C., Reuter, D. A., Haas, S. A., Behem, C. R., Tavazzi, G., Ana, B., Vazir, A., Gibson, D., Price, S., Masjedi, M., Hadavi, M. R., alam, M. Riahi, Sasani, M. R., Parenti, N., Agrusta, F., Palazzi, C., Pifferi, B., Sganzerla, R., Tagliazucchi, F., Luciani, A., Möller, M., Müller-Engelmann, J., Montag, G., Adams, P., Lange, C., Neuzner, J., Gradaus, R., Wodack, K. H., Thürk, F., Waldmann, A. D., Grässler, M. F., Nishimoto, S., Böhm, S. H., Kaniusas, E., Reuter, D. A., Trepte, C. J., Sigmundsson, T., Öhman, T., Redondo, E., Hallbäck, M., Wallin, M., Sipman, F. Suarez, Oldner, A., Sander, C. Hällsjö, Björne, H., Colinas, L., Hernandez, G., Vicho, R., Serna, M., Cuena, R., Canabal, A., Chaari, A., Hakim, K. Abdel, Etman, M., El Bahr, M., El Sakka, A., Bousselmi, K., Arali, A., Kauts, V., Casey, W. F., Bond, O., De Santis, P., Iesu, E., Franchi, F., Vincent, J. L., Creteur, J., Scolletta, S., Taccone, F. S., Marutyan, Z., Hamidova, L., Shakotko, A., Movsisyan, V., Uysupova, I., Evdokimov, A., Petrikov, S., Gonen, C., Haftacı, E., Balci, C., Calvo, F. J. Redondo, Bejarano, N., Baladron, V., Villazala, R., Redondo, J., Padilla, D., Villarejo, P., Akcan-Arikan, A., Kennedy, C. E., Arzapalo, M. F. Aguilar, Gomez-Gonzalez, C., Mas-Font, S., Puppo-Moreno, A., Herrera-Gutierrez, M., Garcia-Garcia, M., Aldunate-Calvo, S., Plata-Menchaca, E. P., Pérez-Fernández, X. L., Estruch, M., Betbese-Roig, A., Campos, P. Cárdenas, Lora, M. Rojas, Gaibor, N. D. Toapanta, Medina, R. S. Contreras, Sanguino, V. D. Gumucio, Casanova, E. J., Riera, J. Sabater, Kritmetapak, K., Peerapornratana, S., Kittiskulnam, P., Dissayabutra, T., Tiranathanagul, K., Susantithapong, P., Praditpornsilpa, K., Tungsanga, K., Eiam-Ong, S., Srisawat, N., Winkelmann, T., Busch, T., Meixensberger, J., Bercker, S., Cabeza, E. M. Flores, Sánchez, M. Sánchez, Giménez, N. Cáceres, Melón, C. Gutierrez, de Lucas, E. Herrero, Estañ, P. Millán, Bernal, M. Hernández, de Lorenzo y Mateos, A. Garcia, Ergin, B., Guerci, P., Specht, P. A. C., Ince, Y., Ince, C., Balik, M., Zakharchenko, M., Los, F., Brodska, H., de Tymowski, C., Augustin, P., Desmard, M., Montravers, P., Stapel, S. N., de Boer, R., Oudemans, H. M., Hollinger, A., Schweingruber, T., Jockers, F., Dickenmann, M., Siegemund, M., Runciman, N., Ralston, M., Appleton, R., Mauri, T., Alban, L., Turrini, C., Sasso, T., Langer, T., Panigada, M., Taccone, P., Carlesso, E., Marenghi, C., Grasselli, G., Pesenti, A., Wibart, P., Reginault, T., Garcia, M., Barbrel, B., Benard, A., Bader, C., Vargas, F., Bui, H. N., Hilbert, G., Simón, J. M. Serrano, Sánchez, P. Carmona, Ferrón, F. Ruiz, de Acilu, M. García, Marin, J., Antonia, V., Ruano, L., Monica, M., Ferrer, R., Masclans, J. R., Roca, O., Hong, G., Kim, D. H., Kim, Y. S., Park, J. S., Jee, Y. K., xiang, Z. Yu, Jia-xing, W., dan, W. Xiao, long, N. Wen, Yu, W., Yan, Z., Cheng, X., Kobayashi, T., Onodera, Y., Akimoto, R., Sugiura, A., Suzuki, H., Iwabuchi, M., Nakane, M., Kawamae, K., Sanchez, P. Carmona, Rodriguez, M. D. Bautista, Delgado, M. Rodriguez, Sánchez, V. Martínez de Pinillos, Gómez, A. Mula, Simón, J. M. Serrano, Beuret, P., Fortes, C., Lauer, M., Reboul, M., Chakarian, J. C., Fabre, X., Philippon-Jouve, B., Devillez, S., Clerc, M., Rittayamai, N., Sklar, M., Dres, M., Rauseo, M., Campbell, C., West, B., Tullis, D. E., Brochard, L., Onodera, Y., Akimoto, R., Suzuki, H., Okada, M., Nakane, M., Kawamae, K., Ahmad, N., Wood, M., Glossop, A., Lucas, J. Higuera, Ortiz, A. Blandino, Alonso, D. Cabestrero, De Pablo Sánchez, R., González, L. Rey, Costa, R., Spinazzola, G., Pizza, A., Ferrone, G., Rossi, M., Antonelli, M., Conti, G., Ribeiro, H., Alves, J., Sousa, M., Reis, P., Socolovsky, C. S., Cauley, R. P., Frankel, J. E., Beam, A. L., Olaniran, K. O., Gibbons, F. K., Christopher, K. B., Pennington, J., Zolfaghari, P., King, H. S., Kong, H. H. Y., Shum, H. P., Yan, W. W., Kaymak, C., Okumus, N., Sari, A., Erdogdu, B., Aksun, S., Basar, H., Ozcan, A., Ozcan, N., Oztuna, D., Malmgren, J. A., Lundin, S., Torén, K., Eckerström, M., Wallin, A., Waldenström, A. C., Riccio, F. C., Pogson, D., Antonio, A. C. P., Leivas, A. F., Kenji, F., James, E., Morgan, P., Carroll, G., Gemmell, L., MacKay, A., Wright, C., Ballantyne, J., Jonnada, S., Gerrard, C. S., Jones, N., Salciccioli, J. D., Marshall, D. C., Komorowski, M., Hartley, A., Sykes, M. C., Goodson, R., Shalhoub, J., Villanueva, J. R. Fernández, Garda, R. Fernández, Lago, A. M. López, Ruiz, E. Rodríguez, Vaquero, R. Hernández, Rodríguez, C. Galbán, Pérez, E. Varo, Hilasque, C., Oliva, I., Sirgo, G., Martin, M. C., Olona, M., Gilavert, M. C., Bodí, M., Ebm, C., Aggarwal, G., Huddart, S., Quiney, N., Cecconi, M., Fernandes, S. M., Silva, J. Santos, Gouveia, J., Silva, D., Marques, R., Bento, H., Alvarez, A., Silva, Z. Costa, Diaz, D. Díaz, Martínez, M. Villanova, Herrejon, E. Palencia, de la Gandara, A. Martinez, Gonzalo, G., Lopez, M. A., de Gopegui Miguelena, P. Ruíz, Matilla, C. I. Bernal, Chueca, P. Sánchez, Longares, M. D. C. Rodríguez, Abril, R. Ramos, Aguilar, A. L. Ruíz, de Murillas, R. Garrido López, Fernández, R. Fernández, Laborías, P. Morales, Castellanos, M. A. Díaz, Laborías, M. E. Morales, Cho, J., Kim, J., Park, J., Woo, S., West, T., Powell, E., Rimmer, A., Orford, C., Jones, N., Williams, J., Matilla, C. I. Bernal, de Gopegui Miguelena, P. Ruiz, Chueca, P. Sánchez, Abril, R. Ramos, Longares, M. D. C. Rodríguez, Aguilar, A. L. Ruíz, de Murillas, R. Garrido López, Bourne, R. S., Shulman, R., Tomlin, M., Mills, G. H., Borthwick, M., Berry, W., Huertas, D. García, Manzano, F., Villagrán-Ramírez, F., Ruiz-Perea, A., Rodríguez-Mejías, C., Santiago-Ruiz, F., Colmenero-Ruiz, M., König, C., Matt, B., Kortgen, A., Hartog, C. S., Wong, A., Balan, C., Barker, G., Srisawat, N., Peerapornratana, S., Laoveeravat, P., Tachaboon, S., Eiam-ong, S., Paratz, J., Kayambu, G., Boots, R., Arzapalo, M. F. Aguilar, Vlasenko, R., Gromova, E., Loginov, S., Kiselevskiy, M., Dolgikova, Y., Tang, K. B., Chau, C. M., Lam, K. N., Gil, E., Suh, G. Y., Park, C. M., Park, J., Chung, C. R., Lee, C. T., Chao, A., Shih, P. Y., Chang, Y. F., Lai, C. H., Hsu, Y. C., Yeh, Y. C., Cheng, Y. J., Colella, V., Zarrillo, N., D’Amico, M., Forfori, F., Pezza, B., Laddomada, T., Beltramelli, V., Pizzaballa, M. L., Doronzio, A., Balicco, B., Kiers, D., van der Heijden, W., Gerretsen, J., de Mast, Q., el Messaoudi, S., Rongen, G., Gomes, M., Kox, M., Pickkers, P., Riksen, N. P., Kashiwagi, Y., Okada, M., Hayashi, K., Inagaki, Y., Fujita, S., Nakamae, M. N., Kang, Y. R., Souza, R. B., Liberatore, A. M. A., Koh, I. H. J., Blet, A., Sadoune, M., Lemarié, J., Bihry, N., Bern, R., Polidano, E., Merval, R., Launay, J. M., Lévy, B., Samuel, J. L., Mebazaa, A., Hartmann, J., Harm, S., and Weber, V.

Published
2016
Full Text
View/download PDF

35. Oncology professionals' perspectives towards cardiac surveillance in breast cancer patients with high cardiotoxicity risk: A qualitative study

Author

Koop, Y., Dobbe, L.C., Maas, A.H.E.M., Spronsen, D.J. van, Atsma, F., El Messaoudi, S., Vermeulen, H., Koop, Y., Dobbe, L.C., Maas, A.H.E.M., Spronsen, D.J. van, Atsma, F., El Messaoudi, S., and Vermeulen, H.

Abstract

Contains fulltext : 232482.pdf (Publisher’s version ) (Open Access), Breast cancer (BC) patients have an increased risk of developing cancer therapy-related cardiac dysfunction (CTRCD) and cardiovascular morbidity, which seems to have a substantial prognostic impact. Oncologists, in collaboration with dedicated cardiologists, have the opportunity to perform cardiovascular risk stratification. Despite guideline recommendations, strategies to detect cardiac damage at an early stage are not structurally implemented in clinical practice. The perspectives of oncology professionals regarding cardiac surveillance in BC patients have not been qualitatively evaluated. We aim to explore the perceptions of oncology professionals regarding cardiac surveillance in BC patients and, more specifically, the influencing factors of delivering cardiac surveillance. A qualitative study with semi-structured interviews was conducted and thematically analyzed. Twelve oncology professionals participated in this study. Four themes were selected to answer the study objectives: (1) sense of urgency, (2) multidisciplinary collaboration, (3) patient burden, and (4) practical tools for cardiac surveillance. Most professionals did not feel the need to deliver cardiac surveillance as they considered the incidence of CTRCD as rare. Multidisciplinary collaboration was also perceived as unnecessary, and cardiac surveillance was considered disproportionately burdensome with respect to its benefits. Nevertheless, professionals affirmed the need for practical tools to deliver cardiac surveillance. Most professionals are currently unaware of CTRCD incidence and cardiac surveillance benefits. Encouraging multidisciplinary collaboration and improving their knowledge of cardiotoxic effects of treatments and possibility of early detection can lead to structured cardiac surveillance for breast cancer patients.

Published
2021

37. Incidence and predictors of vascular complications in transaxillary TAVI

Author

Wulp, K. van der, Thijs, Ina, Wely, M.H. van, Loverbos, Anton, Gehlmann, H.R., Verkroost, M.W., Garsse, L.A. van, Kievit, P.C., Vart, P., El Messaoudi, S., Bosboom, D.G.H., Morshuis, W.J., Royen, N. van, Wulp, K. van der, Thijs, Ina, Wely, M.H. van, Loverbos, Anton, Gehlmann, H.R., Verkroost, M.W., Garsse, L.A. van, Kievit, P.C., Vart, P., El Messaoudi, S., Bosboom, D.G.H., Morshuis, W.J., and Royen, N. van

Abstract

Item does not contain fulltext

Published
2020

38. Reprogramming of bone marrow myeloid progenitor cells in patients with severe coronary artery disease

Author

Noz, M.P., Bekkering, S., Groh, L.A., Nielen, Tim Mj, Lamfers, Evert J.P., Schlitzer, Andreas, El Messaoudi, S., Royen, N. van, Preijers, F.W.M.B., Aarntzen, E.H.J.G., Velden, W.J.F.M. van der, Dolstra, H., Joosten, L.A.B., Netea, M.G., Riksen, N.P., Noz, M.P., Bekkering, S., Groh, L.A., Nielen, Tim Mj, Lamfers, Evert J.P., Schlitzer, Andreas, El Messaoudi, S., Royen, N. van, Preijers, F.W.M.B., Aarntzen, E.H.J.G., Velden, W.J.F.M. van der, Dolstra, H., Joosten, L.A.B., Netea, M.G., and Riksen, N.P.

Abstract

Contains fulltext : 227447.pdf (publisher's version ) (Open Access)

Published
2020

39. Electrocardiography for the detection of left ventricular hypertrophy in an elderly population with long-standing hypertension in primary care: a secondary analysis of the CHELLO cohort study

Author

Hartog-Keyzer, J.M.L. de, El Messaoudi, S., Harskamp, R., Vart, P., Ringoir, L., Pop, V., Nijveldt, R., Hartog-Keyzer, J.M.L. de, El Messaoudi, S., Harskamp, R., Vart, P., Ringoir, L., Pop, V., and Nijveldt, R.

Abstract

Contains fulltext : 225438.pdf (publisher's version ) (Open Access), OBJECTIVES: To investigate: (1) the prevalence of left ventricular hypertrophy (LVH) in elderly primary care patients with long-standing asymptomatic hypertension, and (2) the diagnostic value of ECG as a screening tool in the detection of LVH compared with echocardiography in this specific patient population. DESIGN AND SETTINGS: A cross-sectional study in five general practices in the south-east of the Netherlands. PARTICIPANTS: Patients with primary care-managed hypertension, aged between 60 and 85 years, without known heart failure. PRIMARY AND SECONDARY OUTCOME MEASURES: Between June 2010 and January 2013, the patients underwent structured interviews, blood pressure assessment, laboratory testing, ECGs and echocardiograms. The primary outcome was to investigate the ability of ECG to detect LVH, compared with echocardiography as a reference test (gold standard). RESULTS: Four hundred and twenty-two patients (44% male; ages 70±7 years) who underwent ECG and echocardiographic assessment to determine LVH were included. The median duration of hypertension was 10 (4-15) years. The overall prevalence of LVH was 44%, which increased with age (p<0.001); up to 60% of patients were ≥75 years. ECG intimated LVH in 47 patients (11%) but in only 26 of those (55%) was LVH confirmed by echocardiography. The sensitivity of ECG for detecting LVH was poor (14%). CONCLUSIONS: Asymptomatic primary care patients with long-standing hypertension have a high prevalence of previously undetected LVH, which increases with age. ECG is inadequate for detecting LVH in these patients. Early detection of LVH could potentially create more awareness for the optimal regulation of hypertension and compliance to therapy. Therefore, echocardiography should be considered a screening device for the detection of LVH in this population.

Published
2020

40. Healthcare utilization and hospital variation in cardiac surveillance during breast cancer treatment: a nationwide prospective study in 5000 Dutch breast cancer patients

Author

Koop, Y., El Messaoudi, S., Vermeulen, H., Maas, A.H., Atsma, F., Koop, Y., El Messaoudi, S., Vermeulen, H., Maas, A.H., and Atsma, F.

Abstract

Contains fulltext : 225453.pdf (publisher's version ) (Open Access), BACKGROUND: Various breast cancer (BC) treatments, such as chemotherapy and targeted therapies, increase cardiotoxicity-risk and lead to premature ischemic heart disease and heart failure among survivors. Reducing this adverse risk through early recognition and (preventive) treatment is therefore important. Conversely, we feel that screening for cardiotoxicity is currently insufficiently standardized in daily practice. A fundamental first step in identifying areas of improvement is providing an overview of current practice. OBJECTIVE: This study aims to describe current cardiac surveillance for women with BC during and after cardiotoxic cancer treatment, using routinely collected hospital data in the Netherlands. The study also describes hospital variation in cardiac surveillance. METHODS: This observational study was performed on claims data provided by Statistics Netherlands. From the data, newly diagnosed BC patients in 2013 (N = 16,040) were selected and followed up until 2015. Healthcare utilization analyses were performed for all cardiac and oncologic healthcare activities but with a specific focus on cardiac surveillance healthcare activities. In addition, differences between types and individual hospitals were evaluated. RESULTS: Almost one third of all BC patients received high risk cardiotoxic treatments (N = 5157), but cardiac surveillance was rarely performed. Cardiac care provided to patients mainly consisted of ECGs (52.0%) and MUGA scans (26.5%). Cardiac MRI was performed in 0.7% of the patients, echocardiography in 17.7%, and measurement of Troponin and NT-proBNP in 5.1 and 5.8%, respectively. Moreover, we observed a substantial variation in cardiac surveillance between different hospital types and between individual hospitals. CONCLUSION: This study shows that women treated for BC with cardiotoxic treatments do not receive recommended cardiac surveillance. Standardized approaches in clinical care are lacking, resulting in low rates of diagnostic tes

Published
2020

42. No superiority of ticagrelor over prasugrel in remote myocardial inflammation in patients with acute myocardial infarction with ST elevation: a CMR T1 and T2 mapping study

Author

Zugwitz, D, primary, Everaars, H, additional, Van Der Hoeven, N.W, additional, Janssens, G.N, additional, Vart, P, additional, Van Leeuwen, M.A.H, additional, Van Rossum, A.C, additional, El Messaoudi, S, additional, Riksen, N.P, additional, Van Royen, N, additional, and Nijveldt, R, additional

Published
2020
Full Text
View/download PDF

43. Towards a screening test for cancer by circulating DNA analysis

Author

Tanos, R., primary, Otandault, A., additional, Mollevi, C., additional, Bauer, A., additional, Tousch, G., additional, Picque Lasorsa, L., additional, El Messaoudi, S., additional, Colinge, J., additional, Colombo, P.-E., additional, Jacot, W., additional, Mazard, T., additional, Sayagués, J.M., additional, Gillet, B., additional, Pezet, D., additional, Ychou, M., additional, and Thierry, A.R., additional

Published
2019
Full Text
View/download PDF

44. A systematic review and meta-analysis of the protective effects of metformin in experimental myocardial infarction

Author

Hesen, N.A., Riksen, N.P., Aalders, B., Ritskes-Hoitinga, M., El Messaoudi, S., Wever, K.E., Hesen, N.A., Riksen, N.P., Aalders, B., Ritskes-Hoitinga, M., El Messaoudi, S., and Wever, K.E.

Abstract

Contains fulltext : 177026.pdf (publisher's version ) (Open Access), Metformin improves cardiovascular prognosis in patients with diabetes mellitus, compared to alternative glucose-lowering drugs, despite similar glycemic control. Direct cardiovascular protective properties have therefore been proposed, and studied in preclinical models of myocardial infarction. We now aim to critically assess the quality and outcome of these studies. We present a systematic review, quality assessment and meta-analysis of the effect of metformin in animal studies of experimental myocardial infarction. Through a comprehensive search in Pubmed and EMBASE, we identified 27 studies, 11 reporting on ex vivo experiments and 18 reporting on in vivo experiments. The primary endpoint infarct size as percentage of area at risk was significantly reduced by metformin in vivo (MD -18.11[-24.09,-12.14]) and ex vivo (MD -18.70[-25.39, -12.02]). Metformin improved the secondary endpoints left ventricular ejection fraction (LVEF) and left ventricular end systolic diameter. A borderline significant effect on mortality was observed, and there was no overall effect on cardiac hypertrophy. Subgroup analyses could be performed for comorbidity and timing of treatment (infarct size and mortality) and species and duration of ischemia (LVEF), but none of these variables accounted for significant amounts of heterogeneity. Reporting of possible sources of bias was extremely poor, including randomization (reported in 63%), blinding (33%), and sample size calculation (0%). As a result, risk of bias (assessed using SYRCLE's risk of bias tool) was unclear in the vast majority of studies. We conclude that metformin limits infarct-size and improves cardiac function in animal models of myocardial infarction, but our confidence in the evidence is lowered by the unclear risk of bias and residual unexplained heterogeneity. We recommend an adequately powered, high quality confirmatory animal study to precede a randomized controlled trial of acute administration of metformin in patients un

Published
2017

45. Targeting the adenosine system to limit ischemia-reperfusion injury

Author

El Messaoudi, S., Riksen, N.P., Rongen, G.A.P.J.M., and Radboud University Nijmegen

Subjects
Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16], GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries)
Abstract

Contains fulltext : 161229.pdf (Publisher’s version ) (Open Access) Radboud University, 19 december 2016 Promotores : Riksen, N.P., Rongen, G.A.P.J.M.

Published
2016

46. Targeting the adenosine system to limit ischemia-reperfusion injury

Author

Riksen, N.P., Rongen, G.A.P.J.M., El Messaoudi, S., Riksen, N.P., Rongen, G.A.P.J.M., and El Messaoudi, S.

Abstract

Radboud University, 19 december 2016, Promotores : Riksen, N.P., Rongen, G.A.P.J.M., Contains fulltext : 161229.pdf (publisher's version ) (Open Access)

Published
2016

47. ESICM LIVES 2016: part one : Milan, Italy. 1-5 October 2016

Author

Pizzaballa, M.L., Doronzio, A., Balicco, B., Kiers, H.D., Heijden, W.A. van der, Gerretsen, J., Mast, Q. de, El Messaoudi, S., Rongen, G.A., Gomes, M.E.R., Kox, M., Pickkers, P., Riksen, N.P., Kashiwagi, Y., Okada, M., Hayashi, K., Inagaki, Y., Fujita, S., Nakamae, M.N., Kang, Y.R., Souza, R.B., Liberatore, A.M., Koh, I.H., Blet, A., Sadoune, M., et al., Pizzaballa, M.L., Doronzio, A., Balicco, B., Kiers, H.D., Heijden, W.A. van der, Gerretsen, J., Mast, Q. de, El Messaoudi, S., Rongen, G.A., Gomes, M.E.R., Kox, M., Pickkers, P., Riksen, N.P., Kashiwagi, Y., Okada, M., Hayashi, K., Inagaki, Y., Fujita, S., Nakamae, M.N., Kang, Y.R., Souza, R.B., Liberatore, A.M., Koh, I.H., Blet, A., Sadoune, M., and et al.

Abstract

Contains fulltext : 172380.pdf (publisher's version ) (Open Access)

Published
2016

49. Sunitinib does not attenuate contractile force following a period of ischemia in isolated human cardiac muscle

Author

Thijs, A.M.J., El Messaoudi, S., Vos, J.C.M., Wouterse, A.C., Verweij, V.G.M., Swieten, H.A. van, Herpen, C.M.L. van, Graaf, W.T.A. van der, Noyez, L., Rongen, G.A.P.J.M., Thijs, A.M.J., El Messaoudi, S., Vos, J.C.M., Wouterse, A.C., Verweij, V.G.M., Swieten, H.A. van, Herpen, C.M.L. van, Graaf, W.T.A. van der, Noyez, L., and Rongen, G.A.P.J.M.

Abstract

Contains fulltext : 154029.pdf (publisher's version ) (Closed access), Concerns have been raised about the development of heart failure in patients treated for cancer with angiogenesis inhibitors, such as the tyrosine kinase inhibitor sunitinib. Patients with previous coronary artery disease and hypertension have an increased risk of developing heart failure. Therefore, we studied the effect of sunitinib on the contractility of isolated human atrial trabeculae and the effect on recovery after ischemic stimulation. After informed consent, the atrial appendage of patients undergoing cardiac surgery was harvested and isolated trabeculae were placed in an organ bath with a force transducer. During electrical stimulation, contractile force was measured during normal pacing or after simulated ischemia. Of each patient, one trabecula was perfused with control and one with sunitinib. Contractile force (expressed as percentage of baseline force) declined over time to 57 +/- 8 and 73 +/- 20 % after 150 min of stimulation for solvent- and sunitinib-treated trabeculae, respectively (mean +/- SE; n = 8; p > 0.1). After simulated ischemia and reperfusion, contractile force was 40 +/- 6 % in the control compared to 39 +/- 6 % in the sunitinib-treated trabeculae during the last final 5 min of reperfusion (n = 12; p > 0.1). Sunitinib at low, but clinically relevant, concentrations does not have a direct effect on function of human atrial cardiomyocytes nor does it attenuate the recovery in contractile force of atrial cardiomyocytes after a period of ischemia. A direct and acute toxic effect on cardiomyocytes does not explain the development of heart failure in patients treated with sunitinib.

Published
2015

50. Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes (MetCAB): a double-blind, randomised controlled trial

Author

El Messaoudi, S., Nederlof, R., Zuurbier, C.J., Swieten, H.A. van, Pickkers, P., Noyez, L., Dieker, H.J., Coenen, M.J.H., Donders, A.R.T., Vos, A., Rongen, G.A.P.J.M., Riksen, N.P., El Messaoudi, S., Nederlof, R., Zuurbier, C.J., Swieten, H.A. van, Pickkers, P., Noyez, L., Dieker, H.J., Coenen, M.J.H., Donders, A.R.T., Vos, A., Rongen, G.A.P.J.M., and Riksen, N.P.

Abstract

Contains fulltext : 155124.pdf (publisher's version ) (Closed access), BACKGROUND: During coronary artery bypass graft (CABG) surgery, ischaemia and reperfusion damage myocardial tissue, and increased postoperative plasma troponin concentration is associated with a worse outcome. We investigated whether metformin pretreatment limits cardiac injury, assessed by troponin concentrations, during CABG surgery in patients without diabetes. METHODS: We did a placebo-controlled, double-blind, single-centre study in an academic hospital in Nijmegen (Netherlands) in adult patients without diabetes undergoing an elective on-pump CABG procedure. We randomly assigned patients (1:1) in blocks of ten via a computer-generated randomisation sequence to either metformin hydrochloride (500 mg three times per day) or placebo (three times per day) for 3 days before surgery. The last dose was given roughly 3 h before surgery. Patients, investigators, trial staff, and the statistician were all masked to treatment allocation. The primary endpoint was the plasma concentration of high-sensitive troponin I at 6, 12, and 24 h postreperfusion after surgery, analysed in the per-protocol population with a mixed-model analysis using all these timepoints. Secondary endpoints included the occurrence of clinically relevant arrhythmias within 24 hours after reperfusion, the need for inotropic support, time to detubation, duration of stay in the intensive-care unit, and postoperative use of insulin. This study is registered with ClinicalTrials.gov, number NCT01438723. FINDINGS: Between Nov 8, 2011, and Nov 22, 2013, we randomly assigned 111 patients to treatment (57 to metformin and 54 to placebo). Five patients dropped out from the metformin group, and six from the placebo group. 52 patients in the metformin group and 48 patients in the placebo group were included in the per-protocol analysis. Geometric mean high-sensitivity troponin I increased from 0 mug/L to 3.67 mug/L (95% CI 3.06-4.41) with metformin and to 3.32 mug/L (2.75-4.01) with placebo at 6 h after reperfusio

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results